Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tranexamic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLG known ✓ | P00747 | 1/20 | 0.95 |
| ▸ | PLAT | P00750 | 1/20 | 0.95 |
| ▸ | LMNA | P02545 | 1/20 | 0.95 |
| ▸ | ANPEP | P15144 | 1/20 | 0.50 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | GABRP | O00591 | 1/20 | 0.41 |
| ▸ | GABRD | O14764 | 1/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.41 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.41 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.41 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.41 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.41 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.41 |
| ▸ | GABRE | P78334 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tranexamic Acid SCHEMBL11189660 | 1.00 | PLG (0.95) | PLGPLATLMNAANPEPENPEP | |
| Tranexamic Acid SCHEMBL10723475 | 1.00 | PLG (0.95) | PLGPLATLMNAANPEPENPEP | |
| Tranexamic Acid SCHEMBL10972769 | 1.00 | PLG (0.95) | PLGPLATLMNAANPEPENPEP | |
| Tranexamic Acid SCHEMBL7326280 | 1.00 | PLG (0.95) | PLGPLATLMNAANPEPENPEP | |
| Tranexamic Acid SCHEMBL7323218 | 1.00 | PLG (0.95) | PLGPLATLMNAANPEPENPEP | |
| Tranexamic Acid SCHEMBL10723480 | 1.00 | PLG (0.95) | PLGPLATLMNAANPEPENPEP | |
| Tranexamic Acid SCHEMBL322487 | 0.98 | PLG (1.00) | PLGPLATLMNAANPEPENPEP | |
| Tranexamic Acid SCHEMBL16974 | 0.98 | PLG (1.00) | PLGPLATLMNAANPEPENPEP | |
| Tranexamic Acid SCHEMBL186034 | 0.98 | PLG (1.00) | PLGPLATLMNAANPEPENPEP | |
| Tranexamic Acid SCHEMBL423790 | 0.98 | PLG (1.00) | PLGPLATLMNAANPEPENPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009145378-A1 | GD COMPLEX COMPRISING DTPA-BIS-AMIDE LIGAND AND METHOD FOR PREPARING THE SAME | KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2009-12-03 | — | — | WO | claimed |
| US-4071553-A | Method for the production of trans-4-aminomethyl cyclohexane-1-carboxylic acid | KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JA) | 1978-01-31 | — | — | US | claimed |
| JP-58083663-A | — | — | None | — | — | JP | disclosed |
| CN-117886814-A | PD-1/PD-L1 small molecule inhibitor and application thereof in medicines | 广东东阳光药业股份有限公司 | 2024-04-16 | — | — | CN | disclosed |
| EP-4038052-B1 | PROSTAGLANDIN E2 (PGE2) EP4 RECEPTOR ANTAGONISTS | DOMAIN THERAPEUTICS (FR) | 2024-02-07 | — | — | EP | disclosed |
| CN-114555573-A | Prostaglandin E2(PGE2)EP4Receptor antagonists | 多曼治疗学公司 | 2022-05-27 | — | — | CN | disclosed |
| CN-113943259-A | Amino acid derivative, preparation method and application thereof | 西安禾渼生物医药有限公司 | 2022-01-18 | — | — | CN | disclosed |
| CN-105899494-B | The Gd coordination compound of the conjugate of tranexamic acid containing DO3A- | 韩国庆北国立大学产业学术合作基金会 | 2018-06-15 | — | — | CN | disclosed |
| EP-2116526-B1 | DERIVATES OF SUBSTITUTED TARTARIC AICD AND USAGE FOR PREPARATING BETA SECRETASE INHIBITORS | INST PHARMACOLOGY & TOXICOLOGY ACADEMY MILITARY MEDICAL SCIENCES PLA CHINA (CN) | 2018-04-18 | — | — | EP | disclosed |
| CN-104955823-B | Carboxy-substituted imidazo [1,2-a ] pyridinecarboxamides and their use as stimulators of soluble guanylate cyclase | 拜耳制药股份公司 | 2017-04-19 | — | — | CN | disclosed |
| CN-104955823-A | Carboxy-substituted imidazo [1,2-a ] pyridinecarboxamides and their use as stimulators of soluble guanylate cyclase | Bayer Pharma AG | 2015-09-30 | — | — | CN | disclosed |
| US-20100331345-A1 | DERIVATIVES OF SUBSTITUTED TARTARIC ACID AND USAGE FOR PREPARING BETA-SECRETASE INHIBITORS | INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA (CN) | 2010-12-30 | — | — | US | disclosed |
| WO-2009145378-A1 | GD COMPLEX COMPRISING DTPA-BIS-AMIDE LIGAND AND METHOD FOR PREPARING THE SAME | KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2009-12-03 | — | — | WO | disclosed |
| EP-2116526-A1 | DERIVATES OF SUBSTITUTED TARTARIC AICD AND USAGE FOR PREPARATING BETA SECRETASE INHIBITORS | Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China (CN) | 2009-11-11 | — | — | EP | disclosed |
| EP-0044541-B1 | AMINOCARBOXYLIC ACIDS, AMINO ALCOHOLS, OR THE DERIVATIVES THEREOF, PROCESSES FOR PRODUCTION THEREOF, AND PHARMACEUTICAL COMPOSITION, CONTAINING AT LEAST ONE OF THESE COMPOUNDS | TEIJIN LIMITED (JP) | 1983-09-21 | — | — | EP | disclosed |
| US-4402975-A | ANTIULCER AGENTS | TEIJIN LIMITED (JP) | 1983-09-06 | — | — | US | disclosed |
| JP-S5883663-A | ISOMERIZATION OF 3-(P-(4-AMINOMETHYLCYCLOHEXYLCARBONYL) PHENYL)PROPIONIC ACID | TEIJIN LTD | 1983-05-19 | — | — | JP | disclosed |
| EP-0044541-A1 | Aminocarboxylic acids, amino alcohols, or the derivatives thereof, processes for production thereof, and pharmaceutical composition, containing at least one of these compounds | TEIJIN LIMITED (JP) | 1982-01-27 | — | — | EP | disclosed |
| US-4071553-A | Method for the production of trans-4-aminomethyl cyclohexane-1-carboxylic acid | KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JA) | 1978-01-31 | — | — | US | disclosed |
| US-3950405-A | ANTIPLASMIN AGENTS | MITSUBISHI CHEMICAL INDUSTRIES LTD. (JA) | 1976-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331345-A1 | DERIVATIVES OF SUBSTITUTED TARTARIC ACID AND USAGE FOR PREPARING BETA-SECRETASE INHIBITORS | BACE1, APP, BACE2 | PLG 347/4885PLAT 714/4885LMNA 1694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.